BIOMARKER FOR PREDICTION OF RECURRENCE IN COLORECTAL CANCER PATIENTS
Approximately 20% of colorectal cancer patients with stage II colorectal cancer experience relapse of the disease. Current clinical-pathologic stratification factors do not allow clear identification of these high-risk patients. The invention is a powerful prognostic biomarker in colorectal cancer, especially in early stages (stages I and II), which might help stratifying patients with stage II for adjuvant chemotherapy. The invention provides a gene expression classifier that distinguishes patients with low or high risk of disease relapse in colorectal cancer and that might be used in the clinics to help clinicians identify high-risk patients and choose the most appropriate treatment for a given patient.